Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital
Rhea-AI Summary
Humacyte (Nasdaq: HUMA) announced a credit facility up to $77.5 million with Avenue Venture Opportunities Fund II, L.P., including a four-year term and an initial tranche of $40 million fully funded at close.
Proceeds from the initial tranche were used primarily to retire existing debt. An additional $37.5 million of tranches are available subject to revenue, regulatory approvals, liquidity conditions and lender approval for the third tranche. Management cited plans for expanded Symvess use, interim V012 Phase 3 dialysis results, and a first human coronary tissue engineered vessel study in 2026.
Positive
- Up to $77.5M committed credit facility
- Initial $40M funded at close
- Initial proceeds used to retire existing debt
- Four-year facility term provides multi-year runway
Negative
- Remaining $37.5M contingent on revenue, regulatory and liquidity conditions
- Third tranche requires lender approval, creating execution risk for full financing
News Market Reaction – HUMA
In the Dec 16 session, HUMA declined 5.08%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 20 | Clinical data update | Positive | -4.3% | Multiple VEITHsymposium talks showed durable positive ATEV clinical outcomes. |
| Nov 13 | Conference preview | Positive | -4.8% | Announced six upcoming VEITHsymposium presentations on ATEV clinical use. |
| Nov 12 | Earnings and update | Neutral | -2.3% | Reported Q3 2025 results, early Symvess sales ramp and cash position. |
| Nov 10 | Phase 3 results | Positive | +1.5% | Presented positive two-year Phase 3 dialysis access results for ATEV. |
| Nov 06 | Earnings call notice | Neutral | -9.7% | Announced upcoming Q3 2025 results release and conference call details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive or neutral catalysts have often been followed by negative price reactions, suggesting a pattern of selling into news.
Over the last two months, Humacyte reported clinical, commercial and financial milestones. Positive Phase 3 dialysis data and favorable ATEV™ results at VEITHsymposium on Nov 10 and Nov 20 were followed by +1.5% and -4.27% moves, respectively. Earnings on Nov 12 and a results preview on Nov 6 saw declines of -2.34% and -9.66%. Today’s non-dilutive credit facility fits into a broader effort to fund commercialization and trials while managing prior financing structures.
Key Terms
credit facility financial
principal amount financial
tranche financial
regulatory approvals regulatory
phase 3 medical
coronary bypass graft surgery medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
DURHAM, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has entered into a credit facility with Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital Group, providing up to
"We are pleased to enter into this facility with Avenue as it allows us to retire our existing indebtedness while providing the opportunity for additional non-dilutive financing in the future," said Dale Sander, Chief Financial Officer of Humacyte. "We are looking forward to an exciting 2026, including our plans for expanded use of Symvess® within the U.S. and international markets, interim results from our V012 Phase 3 trial in dialysis, and commencement of the first human study of our coronary tissue engineered vessel (CTEV) in coronary bypass graft surgery."
"We are excited to partner with Humacyte as it embarks on its next chapter of growth. Symvess is addressing significant patient needs and we are looking forward to supporting them in achieving success," said Chad Norman, Senior Portfolio Manager of Avenue Venture Opportunities Fund.
About Avenue Venture Opportunities
The Avenue Venture Debt Funds seek to provide creative financing solutions to high-growth, venture capital-backed technology and life science companies, focusing generally on companies within the underserved segment of the market created by the widening financing gap between commercial banks and larger debt funds. The Avenue Venture Debt funds are part of the larger group of funds of Avenue Capital Group. For additional information on Avenue Capital Group, which is a global investment firm with assets under management of more than
About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.
For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.
Forward-Looking Statements
This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, our cash resources, the availability of future tranches under the loan agreement and our ability to conduct future non-dilutive financings; our plans and ability to commercialize Symvess and, if approved by regulatory authorities, our product candidates, successfully and on our anticipated timelines; the degree of market acceptance of and the availability of third-party coverage and reimbursement for Symvess and, if approved by regulatory authorities, our product candidates; our ability to manufacture Symvess and, if approved by regulatory authorities, our product candidates in sufficient quantities to satisfy our clinical trial and commercial needs; the anticipated benefits of our ATEVs and our CTEVs relative to existing alternatives; our plans and ability to execute product development, process development and preclinical development efforts successfully and on our anticipated timelines; our ability to design, initiate and successfully complete clinical trials and other studies for our product candidates and our plans and expectations regarding our ongoing or planned clinical trials; the anticipated characteristics and performance of our ATEVs and our CTEVs; the implementation of our business model and strategic plans for our business; and the timing or likelihood of regulatory filings, acceptances and approvals. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, competitive and/or reputational factors, and other risks and uncertainties, including those described under the header “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and Form 10-Q for the quarter ended September 30, 2025, each filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com
Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com
